31 completed, 10 terminated, 9 recruiting, 8 unknown. 70 Phase 2, 8 Phase 1, 5 Phase 3.
Follow Alopecia Areata: new trials by email Literature Review of Alopecia Areata trials Research Report on Alopecia Areata
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II Clinical Study of VC005 Tablets in Subjects With Severe Alopecia Areata Drug: VC005 tablets, VC005 tablets, VC005 placebo tablets - Alopecia Areata | Phase 2 | Recruiting | Jiangsu vcare pharmaceutical technology co., LTD | 120 | 2026-08-18 | 2026-08-27 |
| A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) LY4005130, Placebo - Alopecia Areata | Phase 2 | Recruiting | Eli Lilly and Company | 65 | 2026-04-14 | 2026-11-04 |
| Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome Abrocitinib - Atopic Dermatitis, Alopecia Areata | Phase 2 | Recruiting | Icahn School of Medicine at Mount Sinai | 56 | 2026-01-12 | 2026-10-16 |
| A Study of LAD603 in Adults With Alopecia Areata LAD603, Placebo - Alopecia Areata | Phase 2 | Recruiting | Almirall, S.A. | 136 | 2025-12-17 | 2026-05-20 |
| Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata Vancomycin, Neomycin and MTT capsules, Placebo capsules - Alopecia Areata, Alopecia Totalis | Phase 2 | Recruiting | University of Minnesota | 40 | 2025-08-21 | 2026-06-26 |
| Study to Evaluate Safety and Efficacy of SYHX1901 Tablets in Severe Alopecia Areata Patients SYHX1901, Placebo - Severe Alopecia Areata | Phase 2 | Not yet recruiting | CSPC Ouyi Pharmaceutical Co., Ltd. | 156 | 2025-05-26 | 2025-06-03 |
| A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata ALD-102 Solution, Placebo or Control - Alopecia Areata (AA) | Phase 1 / Phase 2 | Active not recruiting | Aldena Therapeutics | 9 | 2025-03-24 | 2026-11-04 |
| Evaluating the Effectiveness and Tolerance of Baricitinib in the Treatment of Acute Alopecia Areata With Active Hair Shedding: A Prospective Open-Label Study Baricitinib - Alopecia Areata | Phase 2 | Not yet recruiting | National Taiwan University Hospital | 30 | 2025-01-23 | 2025-01-28 |
| Safety and Efficacy of Oral NXC-736 in Adult Participants With Moderate and Severe Alopecia Areata NXC736, Placebo - Alopecia Areata | Phase 2 | Recruiting | NEXTGEN Bioscience | 73 | 2024-09-01 | 2026-04-13 |
| Dupilumab in the Treatment of Pediatric Alopecia Areata Dupilumab, Placebo - Alopecia Areata | Phase 2 | Recruiting | Icahn School of Medicine at Mount Sinai | 76 | 2024-07-11 | 2026-09-02 |
| A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata Amlitelimab, Placebo - Alopecia Areata | Phase 2 | Terminated | Sanofi | 166 | 2024-06-06 | 2026-08-10 |
| A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA) Rezpegaldesleukin, Placebo - Alopecia Areata | Phase 2 | Completed | Nektar Therapeutics | 94 | 2024-04-02 | 2026-09-18 |
| Evaluation of Latanoprost Combined With Fractional Erbium- YAG Laser Latanoprost - Alopecia Areata | Phase 1 / Phase 2 | Unknown | Egymedicalpedia | 70 | 2024-02-01 | 2024-04-16 |
| A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Alopecia Areata Participants IMG-007 - Alopecia Areata (AA) | Phase 1 / Phase 2 | Completed | Inmagene LLC | 29 | 2023-09-25 | 2026-02-09 |
| A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA) bempikibart (ADX-914) - Alopecia Areata | Phase 2 | Active not recruiting | Q32 Bio Inc. | 75 | 2023-09-12 | 2026-05-08 |
| Investigate the Efficacy and Safety of Farudodstat Compared With Its Placebo in Adult Alopecia Areata Participants Farudodstat, Placebo - Alopecia Areata | Phase 2 | Unknown | ASLAN Pharmaceuticals | 60 | 2023-04-14 | 2023-12-18 |
| Regeneron AA Multicenter (Dupilumab) Dupilumab, Placebo - Alopecia Areata | Phase 2 | Recruiting | Emma Guttman | 76 | 2023-04-10 | 2026-06-17 |
| To Compare the Efficacy of Weekly Azathioprine Pulse Versus Betamethasone Oral Mini-Pulse in the Treatment of Moderate to Severe Alopecia Areata Azathioprine (AZA), Betamethasone - Alopecia Areata, Alopecia Areata(AA) | Phase 2 | Completed | Sheikh Zayed Medical College | 60 | 2023-03-01 | 2025-01-22 |
| Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata Ruxolitinib - Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced), Alopecia Areata | Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 70 | 2023-01-18 | 2026-11-06 |
| Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata EQ101 - Alopecia Areata, Alopecia | Phase 2 | Completed | Equillium | 36 | 2022-12-19 | 2025-04-10 |
Showing 20 of 70. Sign in to see all of them.
Alopecia universalis (15) · Alopecia (14) · Dermatitis, Atopic (2) · Down Syndrome (2) · Hair Diseases (2) · Hypotrichosis (2) · Skin Diseases (2) · Autoimmune Diseases (1) · Dermatitis (1) · Eczema (1) · Hidradenitis Suppurativa (1) · Immune System Diseases (1) · Inflammation (1) · Lymphoma, Follicular (1)
Skin and Connective Tissue Diseases (70) · Hair Diseases (68) · Hypotrichosis (68) · Skin Diseases (68) · Alopecia (56) · Pathological Conditions, Signs and Symptoms (15) · Pathological Conditions, Anatomical (14) · Immune System Diseases (4) · Abnormalities, Multiple (2) · Chromosome Disorders (2) · Congenital Abnormalities (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Dermatitis (2) · Genetic Diseases, Inborn (2) · Hypersensitivity (2)
Abatacept (3) · dupilumab (3) · ruxolitinib (3) · PF-06651600 (2) · Solutions (2) · Triamcinolone (2) · Triamcinolone Acetonide (2) · baricitinib (2) · tofacitinib (2) · Azathioprine (1) · Betamethasone (1) · Bexarotene (1) · Bimatoprost (1) · Blood Specimen Collection (1) · Interleukin-2 (1)
Columbia University (4) · Concert Pharmaceuticals (4) · Icahn School of Medicine at Mount Sinai (4) · Pfizer (4) · Aclaris Therapeutics, Inc. (3) · University of Minnesota (3) · Eli Lilly and Company (2) · Emma Guttman (2) · Equillium (2) · LEO Pharma (2) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd (2) · Throne Biotechnologies Inc. (2) · Yale University (2) · ASLAN Pharmaceuticals (1) · Ahmed Hassan Nouh MD (1)
United States (48) · Canada (15) · China (9) · Australia (8) · France (5) · Japan (5) · Poland (5) · South Korea (4) · United Kingdom (4) · Egypt (3) · Germany (3) · Argentina (2) · Bulgaria (2) · Chile (2) · Czechia (2)
Julian Mackay-Wiggan, MD, MS (5) · Emma Guttman, MD, PhD (2) · Emma Guttman-Yassky, MD, PhD (2) · Maria K Hordinsky, MD (2) · Angela Christiano, PhD (1) · Brett King, MD (1) · Brett King, MD, PhD (1) · Bruce Randazzo, MD (1) · Colleen E Hamilton, MS (1)
PMID 38263353, PMID 41917311, PMID 42481842, PMID 25896390, PMID 28619556, PMID 37917289, PMID 19620039, PMID 20115946, PMID 21199096, PMID 21712909, PMID 21899919, PMID 22233865, PMID 22833322, PMID 24872229, PMID 25601618, PMID 25676427, PMID 25765294, PMID 27699252, PMID 27699253, PMID 29452121, PMID 30113844, PMID 31245963, PMID 31321800, PMID 32478930, PMID 34460948, PMID 34863853, PMID 34915057, PMID 35334197, PMID 36045513, PMID 36763878, PMID 36855020, PMID 37062298, PMID 37381691, PMID 37403610, PMID 37556146, PMID 37707764, PMID 37991697, PMID 38904749, PMID 38946973, PMID 39141364, PMID 39254890, PMID 39328096, PMID 39441519, PMID 39575597, PMID 39737640, PMID 39962358, PMID 40145547, PMID 40214720, PMID 40261547, PMID 40654284
2025 (2), 2016 (1), 2017 (1), 2018 (1), 2023 (1), R33AR077495 (1), R61AR084210 (1)